-
[Live] The measurement engineer who has been deeply involved in the industry for 10 years explains the selection of temperature measuring instruments in detail
Time of Update: 2022-01-25
"How to choose a temperature measuring instrument" Click on the picture to enter the live broadcast room.
At 14:00 on January 12, "How to choose a temperature measuring instrument" will be broadcast live, please pay attention!
-
Rejecting involution and seeking differences, BPC 2022 will explore a new journey of innovative drug research and development
Time of Update: 2022-01-24
In recent years, in drug development, the proven target/structure/indication has become a red ocean, and the industry's "introduction" will become a shackle. Only source innovation can stand out .
-
BioConExpo 2022 annual event of biopharmaceutical enterprises is scheduled to be held in Hangzhou State Expo in June
Time of Update: 2022-01-24
Why participate?-Leading the latest weather vane of biological drugs, the best choice for exhibits / technology displayBioCon China is a comprehensive professional platform and international annual conference dedicated to building tripartite policy discussions, technical exchanges, product demonstrations, and project cooperation between Chinese biopharmaceutical companies, domestic and foreign regulatory agencies, and the world's leading biopharmaceutical companies .
-
BIFT China 2022 5th China Biopharmaceutical Innovation and Frontier Technology Summit Notice
Time of Update: 2022-01-24
BIFT China 2022 will show you the latest research and development trends and innovative breakthroughs in biological products such as antibody-drug conjugates (ADC), double antibody, CAR-T, gene therapy, and nanobodies .
-
Spotlight on Twist at JP Morgan 2022 to showcase industry-leading enzymatic synthesis
Time of Update: 2022-01-24
Twist Bioscience announced that it has developed an innovative low-cost, trace-free and scalable enzymatic DNA synthesis process .
Twist is leveraging its unique technology to manufacture a broad range of products based on synthetic DNA, including synthetic genes, next-generation sequencing (NGS) preparation tools, and antibody libraries for drug discovery and development .
-
[Live Preview] Maintenance of Purified Water Equipment
Time of Update: 2022-01-24
Good maintenance is the guarantee for the long-term stable operation of purified water equipment and prolonging the service life of the equipment .
-
Shanghai Zhenge Biotechnology Co., Ltd. raised US$100 million in Series C financing, led by Goldman Sachs and Sofina
Time of Update: 2022-01-24
Chen Jianxin, Chairman and CEO of Zhenge Bio, said: "We are delighted to be led by top international investment institutions such as Goldman Sachs Asset Management, Sofina and Novo Holdings in this round of financing, and thank them for their recognition and support of Zhen Ge Bio.
-
Tianjing Biologics Announces Completion of First Patient Dosing in Phase 2 Study of TJ107 and PD-1 Combination Treatment in Solid Tumors
Time of Update: 2022-01-24
12, 2022 /PRNewswire/ -- Imagination (the "Company") (NASDAQ: IMAB) is a biopharmaceutical company moving from clinical stage to commercialization The company is committed to the target biological research of innovative biological drugs, antibody technology, clinical development and product commercialization in China and the United States, and provides new and effective treatment methods for cancer treatment areas that are in urgent need around the world .
-
The French Consul General in Guangzhou led a delegation to inspect the Sino-Singapore Knowledge City Biopharmaceutical Company
Time of Update: 2022-01-23
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
The delegation visited the Planning Office of Sino-Singapore Guangzhou Knowledge City and the commercial production base of Biopharmaceutical Immune Cell Drugs .
-
CStone Announces the Announcement of the Results of the Phase IV Non-Small Cell Lung Cancer Registration Clinical Study Results of Zejimay(R) (Sugelimumab Injection) in The Lancet-Oncology
Time of Update: 2022-01-23
15, 2022 /PRNewswire/ -- CStone Pharmaceuticals (SEHK: 2616), a leading biopharmaceutical company focusing on the research, development and commercialization of innovative immuno-oncology and precision medicines, today Announced that The Lancet Oncology , the world's leading clinical oncology research journal, published online a randomized trial of Zejimet® (sugalimab injection) in the first-line treatment of stage IV non-small cell lung cancer (NSCLC).
-
Genting Xinyao is licensed to globally develop and commercialize the 3CL protease inhibitor from the Singapore Experimental Drug Research and Development Center, which is expected to become a class-leading oral anti-COVID-19 drug
Time of Update: 2022-01-23
Kerui Bo, CEO of Genting Sunyao, said: "EDDC-2214 and subsequent potential 3CL protease inhibitors are promising new drug candidates, which, combined with our existing COVID-19 vaccine program, will make the company's anti-epidemic strategy more effective.
-
Danaher won the "2021 Responsible Brand Award" at the China Charity Festival
Time of Update: 2022-01-23
In April 2021, for their outstanding contributions to safeguarding the process development and large-scale production of China's new crown vaccine, the two operating companies of the Danaher Group, Staufen and Pall, both won the first batch of awards from the China Vaccine Industry Association.
-
CStone Announces The Lancet-Oncology Announcement of a Phase III Registration Clinical Study of Zejima(R) (Sugalimab Injection) in the Treatment of Non-Small Cell Lung Cancer
Time of Update: 2022-01-23
15, 2022 /PRNewswire/ -- CStone Pharmaceuticals (SEHK: 2616), a leading biopharmaceutical company focusing on the research, development and commercialization of innovative immuno-oncology and precision medicines, today Announced that The Lancet Oncology , the world's leading clinical oncology research journal, published online the registration clinical trial of Zejimet® (sugalimab injection) in the treatment of stage III non-small cell lung cancer (NSCLC).
-
Heji Pharmaceutical - the world's first clinical ITK inhibitor Phase I/Ib trial administered to the first patient in China
Time of Update: 2022-01-23
14, 2022 /PRNewswire/ -- Heji Pharmaceuticals today announced that its world's first ITK inhibitor, CPI-818, has entered clinical development for relapse The clinical phase I/Ib trial of refractory T-cell lymphoma was led by Professor Song Yuqin of the Lymphoma Department of Peking University Cancer Hospital, and the first Chinese patient was administered .
-
Spotlight 2022 JP Morgan Conference Illumina Announces Technology Updates and Multiple Collaborations
Time of Update: 2022-01-22
Illumina is leading the $14 billion market for therapy options, deSouza said, highlighting 11 partnerships for TruSight comprehensive oncology assays, including the just-announced partnership with Boehringer Ingelheim, and 34 IVD development partnerships , including a partnership with Agendia announced this week .
-
Spotlight 2022 JP Morgan Conference 10x Genomics plans to launch antibody discovery platform and other new products
Time of Update: 2022-01-22
Saxonov said the kit, which will provide whole transcriptome and partial protein analysis using 10x's Feature Barcoding technology, is scheduled to launch in the middle of this year .
-
Readers who participated in the selection of innovative products, come and see if you have won the prize?
Time of Update: 2022-01-22
Many enthusiastic readers actively participated in the event and cast their votes for the innovative products in their minds .
At the same time, Biotech would like to thank the readers and all readers who actively participated in this event .
-
Major biotechnological breakthrough of Hong Kong research team
Time of Update: 2022-01-21
Weiyang Kuang, Scientific Director of Mengqian Technology, said: "The oral vaccine for COVID-19 developed by us is effective and safe, because the spike protein RBD does not enter the human blood vessels .
-
Effervescent excipients - surface-modified sodium bicarbonate has a registration number
Time of Update: 2022-01-21
Anti-hygroscopic In effervescent tablets and effervescent pouches, each granule must be surface-modified to avoid premature moisture absorption and foaming; the Effer-Soda ® production process ensures that each granule of sodium bicarbonate is treated with sodium carbonate Surface modification can effectively prevent the above problems .
-
Spotlight 2022 JP Morgan Conference PacBio prepares to enter short-read sequencing market
Time of Update: 2022-01-21
Christian Henry, CEO of Pacific Biosciences, told the conference that the company is trying to enter the short-read sequencing market next year .
After acquiring Omniome last year for $800 million, PacBio noted that it plans to develop a new clustering method for use in conjunction with Omniome's sequencing-by-binding (SBB) method .
